{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:10:08Z","timestamp":1765231808360},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/jcp.0b013e3181b2b9f3","type":"journal-article","created":{"date-parts":[[2009,9,5]],"date-time":"2009-09-05T07:23:08Z","timestamp":1252135388000},"page":"461-467","source":"Crossref","is-referenced-by-count":30,"title":["Personality Trait Dimensions and the Pharmacological Treatment of Borderline Personality Disorder"],"prefix":"10.1097","volume":"29","author":[{"given":"Erika F.H.","family":"Saunders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Silk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-9-20210128","first-page":"1","article-title":"Practice guideline for the treatment of patients with borderline personality disorder.","volume":"158","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701685224","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders.","volume":"8","author":"Herpertz","year":"2007","journal-title":"World J Biol Psychiatry"},{"key":"R4-9-20210128","first-page":"195","article-title":"Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation.","volume":"62","author":"Soloff","year":"1998","journal-title":"Bull Menninger Clin"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.yic.0000224784.90911.66","article-title":"Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials.","volume":"21","author":"Nose","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pmh.41","article-title":"The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials.","volume":"2","author":"Duggan","year":"2008","journal-title":"Pers and Men Health"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1037\/0021-843X.92.3.263","article-title":"Prototypic typology and the borderline personality disorder.","volume":"92","author":"Clarkin","year":"1983","journal-title":"J Abnorm Psychol"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1176\/ajp.155.12.1733","article-title":"Axis I comorbidity of borderline personality disorder.","volume":"155","author":"Zanarini","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0010-440X(98)90038-4","article-title":"Axis II comorbidity of borderline personality disorder.","volume":"39","author":"Zanarini","year":"1998","journal-title":"Compr Psychiatry"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0006-3223(02)01326-4","article-title":"The borderline diagnosis III: identifying endophenotypes for genetic studies.","volume":"51","author":"Siever","year":"2002","journal-title":"Biol Psychiatry"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1176\/ajp.148.12.1647","article-title":"A psychobiological perspective on the personality disorders.","volume":"148","author":"Siever","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1521\/pedi.2007.21.5.536","article-title":"Opinions of personality disorder experts regarding the DSM-IV personality disorders classification system.","volume":"21","author":"Bernstein","year":"2007","journal-title":"J Personal Disord"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v65n0118","article-title":"Olanzapine versus placebo in the treatment of borderline personality disorder.","volume":"65","author":"Bogenschutz","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.","volume":"54","author":"Coccaro","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.","volume":"45","author":"Cowdry","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0924-977X(94)90296-8","article-title":"A trial of carbamazepine in borderline personality disorder.","volume":"4","author":"de la Fuente","year":"1994","journal-title":"Eur Neuropsychopharmacol"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archpsyc.1986.01800070070009","article-title":"Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo.","volume":"43","author":"Goldberg","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.162.3.621","article-title":"Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.","volume":"162","author":"Hollander","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4088\/JCP.v62n0311","article-title":"A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","article-title":"Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study.","volume":"26","author":"Loew","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","article-title":"Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.","volume":"57","author":"Nickel","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","article-title":"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.","volume":"163","author":"Nickel","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1176\/appi.ajp.159.12.2048","article-title":"SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.","volume":"159","author":"Rinne","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004714-199502000-00005","article-title":"Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.","volume":"15","author":"Salzman","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4088\/JCP.v65n0314","article-title":"Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder.","volume":"65","author":"Simpson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","article-title":"Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.","volume":"162","author":"Soler","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R30-9-20210128","first-page":"177","article-title":"Amitriptyline and haloperidol in unstable and schizotypal borderline disorders.","volume":"22","author":"Soloff","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1986.01800070081010","article-title":"Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.","volume":"43","author":"Soloff","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1176\/ajp.143.12.1603","article-title":"Paradoxical effects of amitriptyline on borderline patients.","volume":"143","author":"Soloff","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R33-9-20210128","first-page":"177","article-title":"Behavioral dyscontrol in borderline patients treated with amitriptyline.","volume":"23","author":"Soloff","year":"1987","journal-title":"Psychopharmacol Bull"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004714-198908000-00002","article-title":"Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.","volume":"9","author":"Soloff","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder.","volume":"50","author":"Soloff","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.","volume":"150","author":"Cornelius","year":"1993","journal-title":"Am J Psychiatry"},{"key":"R37-9-20210128","first-page":"333","article-title":"Haloperidol vs. phenelzine in continuation therapy of borderline disorder.","volume":"29","author":"Cornelius","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study.","volume":"19","author":"Tritt","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.v62n1103","article-title":"Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.","volume":"62","author":"Zanarini","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004850-199510030-00007","article-title":"Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder.","volume":"10","author":"Coccaro","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research.","volume":"26","author":"Feighner","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STARD): rationale and design.","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(03)00165-3","article-title":"Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).","volume":"53","author":"Sachs","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr Bull"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200910000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:14:40Z","timestamp":1618035280000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200910000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181b2b9f3","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}